G1 Therapeutics to Present at the BIO International Convention

RESEARCH TRIANGLE PARK, N.C., June 10, 2015 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc., a clinical-stage oncology company, announced today that Chief Business Officer Greg Mossinghoff will present a company overview at the BIO International Convention on Wednesday, June 17 at the Pennsylvania Convention Center in Philadelphia. The presentation will begin at 10:30 a.m. in Theater 4, "The Incredible Helix."

For additional information on the conference, please visit: http://convention.bio.org/.

About G1 Therapeutics, Inc.

G1 Therapeutics, Inc. is a privately held clinical-stage pharmaceutical company based in Research Triangle Park, NC that focuses on the discovery and development of novel, small-molecule therapies to address significant unmet needs in oncology. The company is leveraging its proprietary kinase drug discovery platform to advance a pipeline of best-in-class compounds and first-in-class drug candidates that address two markets: CDK4/6 antineoplastics and protection of the bone marrow and immune system from damage by chemotherapy (chemoprotection).

Visit www.g1therapeutics.com for more information.

CONTACT: Mark Velleca, MD, PhD G1 Therapeutics 919-213-9838 mvelleca@g1therapeutics.com Media: Laura Bagby 6 Degrees Communications 312-448-8098 lbagby@6degreespr.com

Source: G1 Therapeutics